Classical Disease-Modifying Antirheumatic Drugs: A Possible Treatment Option for Dementia?
The protective effects of disease-modifying antirheumatic drugs in dementia was evaluated in a retrospective cohort study.
Inflammation
Clinical Outcomes With MTX Monotherapy vs TNFi-MTX Combination Therapy for Early RA
A randomized study sough to evaluate whether methotrexate monotherapy can safely be started before treatment optimization with a tumor necrosis factor inhibitor in patients with early, active RA.
Chronic Inflammatory Disorders May Increase Cardiometabolic, Mortality Risks
The degree of risk for cardiometabolic events and all-cause mortality appeared to increase in participants who took nonsteroidal anti-inflammatory drugs or corticosteroid drugs.
Alcohol Use: Surveying Effects on the Body’s Major Systems
The effects of alcohol on the body’s systems are examined here, with both damaging and potentially protective effects being explored.
Psoriatic Arthritis Strongly Linked With Developing Diabetes Mellitus
Researchers find that higher levels of disease activity predict the development of diabetes mellitus in patients with psoriatic arthritis.
Brief Exercise Sessions Can Reduce Systemic Inflammation
Small study shows 20 minutes on a treadmill can decrease immune cells tied to inflammation.
Amylase-Trypsin Inhibitors and Systemic Inflammation
Amylase-trypsin inhibitors (ATIs) found in wheat have been linked to inflammation in the lymph nodes, kidneys, spleen, and brain, and can worsen symptoms of RA, SLE, and MS.
Paradoxical Activation of TNF-Regulatory Functions by Adalimumab
Therapeutic anti-TNF antibodies, long thought to act primarily via blockade of proinflammatory soluble TNF, appear to also bind membrane-bound TNF supporting regulatory T-cell expansion suppressing further inflammation.
No Functional Improvement in Knee OA With Spironolactone
Knee osteoarthritis treatment with spironolactone did not improve symptoms, physical function, or health-related quality of life in this cohort of patients.
Phase 3 Primary Endpoint Met For New JAK Inhibitor For RA
The efficacy of baricitinib, an experimental small molecule JAK kinase inhibitor, was assessed in a phase 3 trial of patients with rheumatoid arthritis who had either failed treatment with conventional and synthetic DMARDs, or who were not tolerant of DMARD treatment.
